Рабепразол-СЗ

Quick links

Choose a section

Quick links to important sections

Advertisements

Рабепразол-СЗ

Selected form

Advertisements
Advertisements

Overview of Рабепразол-СЗ

What is Рабепразол-СЗ? (Rabeprazole-SZ)

The section below provides an overview of Рабепразол-СЗ, focusing strictly on its identity, composition, class, and general purpose.

Property Description
Active ingredient Rabeprazole sodium
Form Delayed-release tablets (enteric-coated)
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Sustained gastric acid suppression
Origin Synthetic, substituted benzimidazole

Definition, Active Ingredient, and Pharmacological Class

Рабепразол-СЗ is a synthetic, single-ingredient medication classified pharmacologically as a Proton Pump Inhibitor (PPI). Its active component is Rabeprazole sodium, which is a derivative of the substituted benzimidazole chemical class. Rabeprazole is utilized for its acid-suppressing capability.

Unlike antacids, which only neutralize existing acid, PPIs are designed to interfere directly with the final stage of acid production. Rabeprazole is also considered a prodrug, meaning it remains pharmacologically inactive until it is converted into its active form within the specific acidic environment of the stomach’s acid-producing cells, ensuring a targeted effect.

Composition and Specialized Dosage Form

The drug is prepared for oral use primarily as delayed-release (enteric-coated) tablets or capsules. This specialized pharmaceutical form is essential because Rabeprazole sodium is highly sensitive to acid and would be rapidly destroyed by gastric acid if administered without protection.

This acid-resistant coating ensures the active ingredient remains intact as it passes through the stomach and only releases the Rabeprazole into the less acidic environment of the small intestine for absorption. This strategic formulation helps ensure the drug maintains its chemical integrity and bioavailability, which is crucial for its effectiveness in cases requiring consistent acid control.

General Purpose: Sustained Gastric Acid Suppression

The general purpose of Рабепразол-СЗ is to achieve robust, sustained gastric acid suppression. The medicine functions by permanently blocking the proton pump (H^+/K^+-ATPase) in the stomach lining, the mechanism responsible for the final output of acid.

By inhibiting this pump, the medicine reduces the total acidity in the digestive tract. The primary benefit of this action is creating an environment conducive to the natural healing of the esophageal and stomach lining, which may be damaged by excessive acid production.

Regulatory References

  1. Rabeprazole Sodium - DailyMed - NIH
  2. Rabeprazole Sodium Label - DailyMed - NIH
Advertisements

What side effects are possible with Рабепразол-СЗ?

Possible Side Effects and Safety Information

The official safety profile of Rabeprazole sodium is formally classified by government regulatory authorities based on the affected System-Organ-Class and the observed frequency of occurrence.

Frequency-Classified Adverse Reactions

The most frequently reported adverse reactions are classified as common, typically involving the nervous system and gastrointestinal tract. These may include headache, dizziness, nausea, abdominal pain, diarrhea, constipation, flatulence, and general feelings of weakness (asthenia).

Reactions classified as uncommon include insomnia, cough, rhinitis, rash, and changes in liver enzyme levels.

Serious and Duration-Related Safety Patterns

The regulatory safety profile documents rare but serious adverse reactions, which include blood disorders such as thrombocytopenia and neutropenia, as well as severe cutaneous adverse reactions (SCARs), including Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Hepatic encephalopathy has been reported rarely in patients with pre-existing severe hepatic impairment.

Certain risks are formally associated with long-term use (typically one year or longer). These duration-related patterns include an increased risk of bone fractures of the hip, wrist, or spine, and potential for hypomagnesemia (low magnesium levels). Subacute Cutaneous Lupus Erythematosus (SCLE) may also occur months or years after treatment initiation.

Rabeprazole is formally restricted by a contraindication for individuals with known hypersensitivity to the active substance or substituted benzimidazoles. The label notes that symptomatic response does not exclude the presence of underlying gastric malignancy, a key safety consideration prior to treatment.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory information for Rabeprazole sodium is defined by a limited profile of reported overexposures.

Overdose Scope Official Regulatory Finding
Documented Manifestations Accidental exposures (up to 80 mg) have been associated with no clinical signs or symptoms. Effects are generally minimal and reversible without further medical intervention.
Emergency Action Immediate medical attention is required in the event of any suspected overexposure, even without symptoms. Individuals must contact a Poison Control Centre immediately.
Antidote & Procedures No specific antidote is known. The drug is not readily dialyzable due to extensive protein binding. Treatment is mandated to be symptomatic and supportive.

Official Regulatory Stance on Overdose Management

The official profile characterizes overexposure effects as minimal, yet the regulatory label explicitly mandates that individuals seek immediate medical attention and contact a Poison Control Centre for management guidance. This action leads to supportive and symptomatic treatment, which is consistent with the official statements that no specific antidote exists and that the compound is not dialyzable. There are no population-specific overdose management considerations explicitly documented in the regulatory sections for elderly patients or those with impaired organ function.

Advertisements

Therapeutic Uses of Рабепразол-СЗ

What Рабепразол-СЗ treats: main uses and benefits

Rabeprazole is a medication that is applied across domains where additional symptomatic support is needed. It is commonly used across conditions presenting with acute episodes and is relevant for easing symptoms that interfere with daily comfort.

Rabeprazole is applied in clinical settings that involve acute or unstable symptom patterns. It is applied in scenarios where additional management of discomfort is required for contexts such as erosive or ulcerative gastroesophageal reflux disease (GERD), symptomatic GERD, duodenal ulcers, inflammatory processes linked to Helicobacter pylori, and pathological hypersecretory conditions like Zollinger-Ellison syndrome. The medication is often used during phases when symptoms become more noticeable.

It provides support that helps ease the overall symptom burden. This application supports the patient during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms. Furthermore, it assists with maintaining functional stability and managing symptoms that create noticeable physiological strain.


Quick Fact: Relevant for easing symptoms related to physical discomfort

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Рабепразол-СЗ (Rabeprazole Sodium)

Official regulatory information defines specific populations eligible for the use of rabeprazole, as well as strict contraindications that prohibit its use.


Absolute Contraindications

Rabeprazole is formally contraindicated and must not be used in the following populations:

  • Individuals with a known history of hypersensitivity to rabeprazole or any related substituted benzimidazoles (the pharmacological class).
  • Patients who are concurrently receiving rilpivirine-containing products.

Age-Based and Special Population Eligibility

Population Group Eligibility Status Key Restriction/Condition
Adults (18+), Adolescents (12+) Use is established. Standard eligibility for treatment.
Children (1–11 years) Use is established. Not recommended for children under 1 year of age (use not established).
Severe Hepatic Impairment Use requires caution. Caution is mandated due to limited clinical data.
Renal Impairment Use is permitted. No dosage adjustment is necessary for patients with kidney disease.
Pregnancy/Lactation Conditional use. No adequate studies exist; use only if potential benefit justifies potential risk.

The official label mandates that use in patients with severe hepatic impairment requires caution. For pregnant and breastfeeding women, use is conditional upon assessing the benefits against the potential risks, due to a lack of established safety data. These constraints strictly delineate the population groups for which the medicine is officially authorized or expressly prohibited by regulatory authorities.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Рабепразол-СЗ (Rabeprazole sodium) has officially documented interaction patterns that are primarily driven by its effect on gastric acidity and its hepatic metabolism. The reduction of gastric acid can alter the systemic exposure of co-administered medicines whose absorption is pH-dependent.

Documented Pharmacological Interactions

Interaction Type Interacting Agents Official Interaction Outcome
Contraindicated Combination Rilpivirine-containing products Substantial decrease in Rilpivirine plasma concentration is documented, risking loss of antiviral efficacy.
Absorption Alteration Ketoconazole, Atazanavir, Iron salts Co-administration may decrease the systemic exposure and therapeutic effect of these agents.
Exposure Increase Digoxin Studies show Rabeprazole co-administration may increase the C max and AUC of Digoxin.
Antineoplastic Risk High-dose Methotrexate Concomitant use may elevate and prolong serum concentrations of Methotrexate. Regulatory documents suggest considering temporary withdrawal of Rabeprazole.
Anticoagulant Risk Warfarin Post-marketing reports indicate an association with increases in INR and prothrombin time.

The official interaction profile also notes that the medicine is metabolized through CYP2C19 and CYP3A4; however, interactions with agents like theophylline, diazepam, and phenytoin are not considered clinically significant. Systemic concentrations of Rabeprazole are documented to be higher in CYP2C19 poor metabolizers.

Advertisements

Mechanism of Action

Irreversible Inhibition of the Gastric Proton Pump

Рабепразол-СЗ is a selective inhibitor that targets the final stage of acid production by covalently binding to the H^+/ K^+-ATPase enzyme, or Proton Pump, found exclusively in the stomach's parietal cells. This permanent chemical blockade functionally dismantles the enzyme's ability to transport H^+ ions, resulting in a direct suppression of the primary mechanism of hydrochloric acid secretion.


Acid-Dependent Prodrug Activation

The drug acts as an inactive prodrug that requires the low pH environment of the parietal cell's secretory canaliculus to convert into its active sulfenamide form. This specialized, acid-catalyzed activation localizes the drug's effect to the site of acid production, influencing the suppression of both basal and stimulated acid output.


Sustained Regulation of Gastric Acidity

Because the molecular bond formed is covalent and irreversible, the enzyme remains blocked for its entire lifecycle, causing the drug's suppressive effect to persist long after the substance has cleared from the bloodstream. The sustained physiological consequence is a prolonged elevation of the pH within the gastric lumen, as the restoration of full acid secretion capacity depends on the body's rate of synthesizing new, functional proton pumps.

Advertisements

Dosage and Administration Information

How to Use Рабепразол-СЗ

Рабепразол-СЗ (rabeprazole sodium) is a medication with specific administration parameters to ensure appropriate use. The medicine is primarily administered via the oral route using delayed-release tablets, although an intravenous formulation may be used in hospital settings in some countries.

Administration and Timing

Administration of the delayed-release tablet requires the medicine to be swallowed whole with water. The tablet must not be chewed, crushed, or split under any circumstances, as its integrity is crucial for protecting the active ingredient from stomach acid.

For most uses, including the healing of erosive disease, the tablet may be taken with or without food. However, certain applications, such as for duodenal ulcers, specify taking the dose after the morning meal. For the Helicobacter pylori eradication regimen, the 20 mg dose is typically administered twice daily with the morning and evening meals.

Dosing and Course Duration

Most adult regimens rely on a 20 mg dose taken once daily for initial treatment. Pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, require a higher starting dose of 60 mg once daily, which may be adjusted up to a total of 120 mg per day.

Treatment follows standardized patterns, including short-term courses (typically 4 to 8 weeks) for acute healing and long-term continuous use for maintenance therapy or chronic conditions. In the event of a missed dose, the standard procedure is to take it as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

No dosage adjustment is necessary for older adults or patients with renal impairment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Рабепразол-СЗ

Evidence for Healing and Maintenance in Erosive GERD

The foundation of research for this medicine is built on Randomized Controlled Trials (RCTs) and observational studies primarily involving adults and adolescents. These short-term RCTs, often lasting 4 to 8 weeks, examined the endoscopic healing rates of the esophageal lining and patient-reported outcomes describing perceived discomfort. For patients who achieved initial healing, longer-term RCTs were studied for continuous administration, monitoring measured outcomes related to the prevention of endoscopic relapse over periods extending up to five years. Comparative evidence exploring whether lower doses are the same as higher doses remains subject to scientific discussion.

Evidence for Symptom Management and Ulcer Healing

Research explored whether the medicine was relevant in trials assessing short-term or episodic symptom patterns, such as in patients with GERD symptoms but no visible damage (Non-Erosive Reflux Disease). Short-term RCTs focused on outcomes reflecting daily functioning, specifically the resolution of daytime and nighttime heartburn. The medicine was also evaluated in studies designed to measure the rate of duodenal ulcer healing in conditions presenting with acute episodes.

Evidence for H. pylori Eradication

The medicine was studied for its application in research exploring the eradication of the Helicobacter pylori bacteria. Clinical trials evaluated this medicine as a critical component of specific, three-drug combination therapies, alongside antibiotics. Studies reported bacterial eradication rates and monitored the incidence of duodenal ulcer recurrence. A key limitation is that research findings are contingent upon the specific antibiotics used and local bacterial resistance patterns, which may vary across different study settings.

Evidence in Specific or Vulnerable Populations

Dedicated research was studied for adolescents (12 years and older) with GERD and for older adults on long-term low-dose aspirin therapy. These studies monitored cumulative recurrence rates of peptic ulcers over periods up to several years. However, the patient populations in these specific trials were often defined by complex comorbidities, meaning the results apply only to the populations studied.

Key Evidence Gaps and Areas of Research Uncertainty

While an extensive amount of research was observed in research related to the main indications, several areas of uncertainty remain. Evidence quality varies across studies, and some limitations exist, such as follow-up durations being limited in certain acute treatment contexts. The specific focus of the research on defined populations means that generalizability may be uncertain for all patient groups.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Рабепразол-СЗ (FAQ)


Q: Is Rabeprazole-SZ considered the same medication as the generic rabeprazole?

A: The official product information states that Rabeprazole-СЗ contains the active ingredient rabeprazole sodium. This is the same active ingredient found in generic rabeprazole products. Regulatory agencies confirm that generic and brand-name products must contain the same active ingredient and be considered bioequivalent, meaning they work in the body in the same way. The -СЗ suffix denotes a specific manufacturer or local brand.


Q: What specific conditions are treated by this type of acid-reducing drug?

A: According to official regulatory documents, rabeprazole is indicated for several acid-related conditions. These include the healing and maintenance of erosive or ulcerative gastroesophageal reflux disease ( GERD) and the treatment of symptomatic GERD. It is also used in therapies to heal duodenal ulcers and as a component of the regimen to eradicate the Helicobacter pylori bacteria.


Q: Does this medicine completely stop the production of stomach acid?

A: Rabeprazole is designed to produce a profound and long-lasting inhibition of acid secretion by blocking the H^+/ K^+-ATPase (proton pump) in the stomach lining. While this action significantly suppresses acid output, the effect is not permanent. The body continually synthesizes new acid pumps, which eventually allows for the restoration of acid secretion over time.


Q: Are there specific vitamins or supplements that are generally cautioned against with this medicine?

A: Official information notes that reducing stomach acid can alter the systemic exposure of certain substances whose absorption is pH-dependent. This includes Iron salts and Vitamin B12 (cyanocobalamin). Official guidance indicates that monitoring may be considered for patients on long-term treatment who have risk factors for low B12 levels.


Q: Are there any specific contraindications or warnings for elderly patients?

A: While no dose adjustment is typically necessary for older adults, official warnings exist regarding long-term use of this class of medication. Use for a year or longer may modestly increase the risk of certain bone fractures (hip, wrist, and spine). This risk is seen more often in the elderly population.


Q: How does this drug differ from an H2 blocker like famotidine?

A: Rabeprazole is classified as a Proton Pump Inhibitor ( PPI). It works by permanently inhibiting the final step of acid production inside the stomach cells. In contrast, H2 blockers only block specific receptors that stimulate acid production. This difference in mechanism allows PPIs like rabeprazole to be associated with a sustained and potent suppression of acid, reflecting the mechanism of action.


Q: What official guidance exists on when it is time to stop taking the medication?

A: The duration of treatment is typically standardized for the condition being managed, such as 4 to 8 weeks for acute healing. Regulatory documents indicate a recommendation to use the lowest dose and shortest duration that is appropriate for the condition being managed, due to risks associated with long-term use. The criteria and process for stopping the medicine are determined by a healthcare provider.


Q: Is there a concern about experiencing a rebound in acid when discontinuing this medication?

A: Literature associated with regulatory review discusses the phenomenon of rebound hyperacidity. This is an increase in acid secretion above pre-treatment levels that can occur if the medication is stopped suddenly. This temporary increase in acid production may cause a return of symptoms.


Q: What is the concern about Vitamin B12 levels with this class of medication?

A: Official safety information indicates that daily use for longer than three years may be associated with the malabsorption of Vitamin B12 (cyanocobalamin). This potential effect is noted in the safety profile. Official documentation states that a deficiency diagnosis is a factor for consideration if clinical symptoms of B12 deficiency are observed during long-term use.


Q: What types of food or drinks are described as interacting with this drug?

A: Official product instructions confirm that for most conditions, the medicine can be taken with or without food. However, for certain indications, the official administration instructions specify taking the dose relative to a meal. The regulatory information focuses primarily on administration timing and does not list specific food components as pharmacological interactions.


Q: Is it true that taking this drug can increase the risk of certain infections?

A: Official regulatory warnings note that PPI therapy may be associated with an increased risk of specific infections. These include gastrointestinal infections such as Salmonella and Campylobacter. Additionally, this class of drug may be associated with an increased risk of ** Clostridium difficile-associated diarrhea ( CDAD).

Advertisements

How should Рабепразол-СЗ be stored and disposed of?

How to Store and Dispose of Rabeprazole (Рабепразол-СЗ)

Official Storage Requirements

Rabeprazole must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions between 15 C and 30 C (59 F and 86 F). The medicine must be kept in its original container and the container must remain tightly closed and stored in a dry place to maintain stability.

Handling and Protection

As regulatory documents confirm the drug is acid-labile, the tablets or capsules must be swallowed whole and not be chewed, crushed, or split to protect the essential enteric coating. The product should not be used if the expiration date has passed.

Official Disposal Instructions

Do not flush rabeprazole down the toilet or pour it down a drain. The preferred method for disposal is using a regulated drug take-back program or mail-back service. If take-back is unavailable, the drug should be mixed with an unappealing substance (like dirt or used coffee grounds), placed in a sealed bag, and discarded in household trash to prevent accidental exposure to children or pets. Environmental discharge must be avoided.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Рабепразол-СЗ found in:

A-Z Index: